Aprepitant: an oral NK1 antagonist for the prevention of nausea and vomiting induced by highly emetogenic chemotherapy.
Drugs Today (Barc)
; 40(10): 853-63, 2004 Oct.
Article
em En
| MEDLINE
| ID: mdl-15605119
ABSTRACT
This paper reviews the clinical profile of aprepitant, the first neurokinin-1 (NK(1)) receptor antagonist to be approved for use in the prevention of chemotherapy-induced nausea and vomiting. When given to patients receiving highly emetogenic chemotherapy, aprepitant in combination with a 5-hydroxytryptamine type-3 (5HT(3)) receptor antagonist and a corticosteroid provides significantly improved protection from chemotherapy-induced nausea and vomiting over that which has been previously achievable with current antiemetics.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Vômito
/
Morfolinas
/
Receptores da Neurocinina-1
/
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos
/
Antagonistas dos Receptores de Neurocinina-1
/
Antieméticos
/
Náusea
Limite:
Humans
Idioma:
En
Revista:
Drugs Today (Barc)
Assunto da revista:
MEDICINA OCUPACIONAL
/
SAUDE AMBIENTAL
Ano de publicação:
2004
Tipo de documento:
Article
País de afiliação:
Estados Unidos